+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy

Blood Advances 1(25): 2320-2324

Management for patients with antiphospholipid syndrome (APS) and arterial thrombosis is controversial. There are no prospective data demonstrating the superiority of high- or moderate-intensity anticoagulation with vitamin K antagonists over antiplatelet agents. Using 2 antiphospholipid antibody databases (single center [New York Presbyterian Hospital] and multicenter [Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking]), we retrospectively collected demographic and clinical data of patients with APS and arterial thrombosis. The primary outcome was recurrent thrombosis rate after initial arterial thrombosis in patients with APS treated with antiplatelet and/or anticoagulant therapy. We identified 139 patients with a median follow-up time of 4.24 years after initial thrombosis. Thirty-seven patients (27.3%) received anticoagulants, 43 (30.9%) antiplatelets, and 58 (41.7%) combined therapy. Sixteen patients (37.2%) in the antiplatelet group, 9 (23.7%) in the anticoagulant group, and 4 (6.9%) in the combined therapy group experienced recurrent thrombosis. We estimate that 20% of patients will experience a recurrence by 3.4, 7.3, and 16.3 years, respectively, depending on assignment to antiplatelet, anticoagulant, or combined therapy. These results suggest that combined therapy decreases the rate of and increases the time to thrombosis recurrence in patients with APS presenting with arterial thrombosis.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 065465742

Download citation: RISBibTeXText

PMID: 29296881

DOI: 10.1182/bloodadvances.2017008185

Related references

Antiphospholipid antibodies and thrombosis: association with acquired activated protein C resistance in venous thrombosis and with hyperhomocysteinemia in arterial thrombosis. Thrombosis and Haemostasis 92(6): 1312-1319, 2004

A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). Journal of Thrombosis and Haemostasis 3(5): 848-853, 2005

Thrombosis of the terminal aorta, deep vein thrombosis, recurrent fetal loss, and antiphospholipid antibodies. Vasa 25(2): 194-199, 1996

More about the link between thrombosis and atherosclerosis in autoimmune diseases: triglycerides and risk for thrombosis in patients with antiphospholipid antibodies. Journal of Rheumatology 21(12): 2394, 1994

Association between antiphospholipid antibodies and arterial thrombosis in patients with rheumatoid arthritis. Lupus 26(1): 88-94, 2016

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. Haematologica 103(7): E315-E317, 2018

Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis and Rheumatism 61(1): 29-36, 2009

Antiphospholipid sydrome--recurrent thrombosis and foetal loss due to antiphospholipid antibodies. Srpski Arhiv Za Celokupno Lekarstvo 122(5-6): 179-181, 1994

Antiphospholipid antibodies and splenic thrombosis in a patient with idiopathic myelofibrosis (antiphospholipid antibodies and thrombosis). Haematologica 77(6): 516-517, 1992

A Randomized Trial of Two Intensities of Warfarin for the Prevention of Recurrent Thrombosis in Patients with Antiphospholipid Antibodies. Blood 100(11): Abstract No 555, November 16, 2002

Antiphospholipid Antibodies Is a Risk Factor for Thrombosis and FVIIa and Phosphatidyl Ethanolamine Are Most Frequent Antigens in Patients with Clonal Thrombocytosis and Thrombosis. Blood 100(11): Abstract No 3804, November 16, 2002

Anti-b 2 -Glycoprotein I and Antiphosphatidylserine Antibodies Are Predictors of Arterial Thrombosis in Patients With Antiphospholipid Syndrome. American Journal of Clinical Pathology 121(1): 142-149, 2004

Prevalence and isotype distribution of antiphospholipid antibodies in unselected Chilean patients with venous and arterial thrombosis. Clinical Rheumatology 23(2): 129-133, 2004

Anticardiolipin immunoglobulin G subclasses Association of IgG2 with arterial and venous thrombosis in patients with antiphospholipid antibodies. Arthritis & Rheumatism 39(9 Suppl. ): S319, 1996

Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. American Journal of Clinical Pathology 121(1): 142-149, 2004